Department of Pediatrics
Congenital, Hereditary, and Neonatal Diseases and Abnormalities | Endocrine System Diseases | Endocrinology, Diabetes, and Metabolism | Immunology and Infectious Disease | Infectious Disease | Nutritional and Metabolic Diseases | Respiratory Tract Diseases | Virus Diseases
The novel SARS-CoV-2 coronavirus (COVID-19) has become a global health crisis since its initial outbreak in Wuhan, China in December 2019. On January 30, 2020, the WHO recognized the COVID-19 outbreak as a Public Health Emergency, and on March 11, 2020, it was declared a pandemic. Although all age groups have been affected, patients with cystic fibrosis (CF) and patients with type 1 or type 2 diabetes have been categorized as highly vulnerable to SARS-CoV-2 infection. Thus far, studies have found that the incidence of SARS-CoV-2 in the CF population is lower than the general population. We review the underlying protective mechanisms which may reduce inflammation and lung damage in CF patients, thus decreasing their risk of severe COVID-19. While the effect of SARS-CoV-2 in those with diabetes related to CF is unknown, other forms of diabetes have been associated with more severe disease. To further understand the potential impact of SARS-CoV-2 in cystic fibrosis-related diabetes, we provide a comprehensive overview of the potential factors contributing to COVID-19 severity in other forms of diabetes, including direct viral effect on the pancreas and indirect effects related to hyperglycemia and immune dysregulation.
ACE2, COVID-19, Cystic fibrosis, Cystic fibrosis-related diabetes, Diabetes, SARS-CoV-2
Rights and Permissions
© 2021 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
DOI of Published Version
Mason K, Hasan S, Darukhanavala A, Kutney K. COVID-19: Pathophysiology and implications for cystic fibrosis, diabetes and cystic fibrosis-related diabetes. J Clin Transl Endocrinol. 2021 Dec;26:100268. doi: 10.1016/j.jcte.2021.100268. Epub 2021 Oct 25. PMID: 34722160; PMCID: PMC8545686. Link to article on publisher's site
Journal of clinical and translational endocrinology
Mason K, Hasan S, Darukhanavala A, Kutney K. (2021). COVID-19: Pathophysiology and implications for cystic fibrosis, diabetes and cystic fibrosis-related diabetes. COVID-19 Publications by UMass Chan Authors. https://doi.org/10.1016/j.jcte.2021.100268. Retrieved from https://escholarship.umassmed.edu/covid19/375
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.
Congenital, Hereditary, and Neonatal Diseases and Abnormalities Commons, Endocrine System Diseases Commons, Endocrinology, Diabetes, and Metabolism Commons, Immunology and Infectious Disease Commons, Infectious Disease Commons, Nutritional and Metabolic Diseases Commons, Respiratory Tract Diseases Commons, Virus Diseases Commons